Voltar
Artigo Revisado por pares
BIBTEX RIS

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

2024; Massachusetts Medical Society; Volume: 391; Issue: 3 Linguagem: Inglês

10.1056/nejmoa2314585

ISSN

1533-4406

Autores

Laurent Peyrin‐Biroulet, J. Casey Chapman, Jean–Fréderic Colombel, Flavio Caprioli, Geert R. D’Haens, Marc Ferrante, Stefan Schreiber, Raja Atreya, Silvio Danese, James O. Lindsay, Peter Bossuyt, Britta Siegmund, Peter M. Irving, Remo Panaccione, Qian Cao, Ezequiel Neimark, Kori Wallace, Toni Anschutz, Kristina Kligys, W. Rachel Duan, Valerie Pivorunas, Xiu Huang, Sofie Berg, Lei Shu, Marla C. Dubinsky,

Tópico(s)

Microscopic Colitis

Resumo

The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown.

Referência(s)